Sun Pharma Advanced Research Co Ltd has seen its stock value climb by 99.05% over the previous six months and 71.92% throughout the last year. The company is currently trading at a P/E ratio of 5.66, which is significantly lower than the industry standard of 35. This upward trend is driven by improvements in cost efficiency, advancements in its clinical pipeline, a possible $100 million boost, and increased investment from foreign institutional investors.
by shortkt.com✓